Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Wolfsberg – page 7

78 clinical trials in Wolfsberg, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Wolfsberg at a glance
78
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

78 trials in Wolfsberg

Open in trial search

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Diabetic neuropathy+1

Not recruiting

Study on the Effectiveness and Safety of AP707, Amitriptyline, and Capsaicin for Patients with Chronic Pain from Diabetic Neuropathy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen - Cilag International

Type 2 diabetes mellitus+3

Not recruiting

Evaluating Once Daily Orforglipron (LY3502970) Compared to Insulin Glargine in Adults with Type 2 Diabetes and Obesity or Overweight who Have Increased Cardiovascular Risk

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Canagliflozin
  • Sponsor:Eli Lilly & Co.

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Crohn's disease

Not recruiting

Study of AZD7798 compared to placebo in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:AZD7798
  • Sponsor:Astrazeneca AB

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Wolfsberg

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive breast cancer treatment optimization. The research explores enhanced therapeutic approaches for patients with HER2-negative early breast cancer.

  • Treatment Enhancement Studies
  • Endocrine Therapy Research
  • Disease-Free Survival Analysis

Current investigations evaluate the effectiveness of combining standard endocrine therapy with novel therapeutic agents to improve patient outcomes in early-stage breast cancer treatment.

02 Oncology Therapeutics

Advanced research examining the potential of combination therapy approaches in breast cancer treatment. Studies focus on evaluating long-term treatment strategies spanning multiple years.

  • Combination Treatment Protocols
  • Long-term Therapeutic Outcomes
  • Invasive Disease Management

The research aims to establish more effective treatment protocols for patients with hormone-sensitive breast cancer through innovative therapeutic combinations.

03 Clinical Outcomes Research

Comprehensive studies analyzing invasive disease-free survival in breast cancer patients. The research evaluates the impact of enhanced treatment protocols on patient outcomes.

  • Survival Rate Analysis
  • Treatment Response Assessment
  • Long-term Patient Monitoring

These trials focus on gathering crucial data about treatment effectiveness and patient response in early-stage breast cancer management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.